查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1609961

乙醯胺酚靜脈注射液市場規模、佔有率、趨勢分析報告：按適應症、應用、最終用途、地區和細分市場預測，2025-2030 年

Paracetamol IV Market Size, Share & Trends Analysis Report By Indication (Pain, Pyrexia), By Application (Surgical, Non-surgical), By End Use (Hospitals, Clinics), By Region (North America, Asia Pacific), And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

乙醯胺酚靜脈注射市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，預計2030年全球乙醯胺酚靜脈注射液市場規模將達到9.9423億美元，2025-2030年複合年成長率為3.43%。

需要疼痛管理的慢性疾病盛行率的上升預計將在預測期內推動該行業的成長。擴大使用對乙醯胺酚來減少鴉片類藥物對疼痛治療的依賴，預計將加速靜脈注射乙醯胺酚的需求成長。靜脈注射乙醯胺酚是一種穩定的對乙醯胺酚製劑，用於治療輕度至中度疼痛。乙醯胺酚不會抑制血小板功能，因此比其他非類固醇消炎劑更常用於治療有消化性潰瘍或氣喘病史的患者。

隨著抱怨術後疼痛的患者數量增加，對副作用較少的藥物和產品的需求預計將會增加。 《國際外科雜誌》發表的論文顯示，2022年3月，美國77%至83%的患者、泰國80%的患者、瑞典76%的患者、德國29.5%的患者將接受手術。報告說有嚴重到中度的背痛。靜脈注射乙醯胺酚用於治療術後急性疼痛以及在整形外科、牙科、婦科等手術中使用。由於手術數量的增加和術後疼痛患者的增加，預計未來幾年對該產品的需求將會很高。然而，多種非專利藥的上市預計將在預測期內阻礙該行業的發展。

例如，2020年12月，山德士國際有限公司在美國推出了對乙醯胺酚注射液的學名藥。本產品將以 10 mg/mL 的濃度裝在 100 mL管瓶中，與鴉片類止痛藥合併用於治療兒科病患的輕度至中度病症。世界各地各行業的主要企業正在採取各種策略舉措來擴大業務並獲得相對於其他公司的競爭優勢。例如，2021 年 12 月，Leucadia Pharmaceuticals 推出並宣布了對乙醯胺酚注射液，這是 FDA核准的對乙醯胺酚注射液的非專利藥，由 Mallinckrodt Pharmaceuticals 生產。

乙醯胺酚靜脈注射市場報告亮點

  • 從應用來看，預計 2025 年至 2030 年，供熱領域的複合年成長率最快。
  • 這一領域的成長歸因於乙醯胺酚靜脈注射的快速起效和有效性。
  • 2024年，由於靜脈注射乙醯胺酚用於治療術後疼痛和快速退燒的使用量增加，外科應用領域佔據了最大的銷售佔有率。
  • 由於產品使用量高，以減少經濟對用於疼痛管理的鴉片類藥物的依賴，北美將在 2024 年主導全球產業。
  • 公司專注於地域擴張，採取聯盟、夥伴關係、新產品發布和策略舉措等策略來維持行業競爭力。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章乙醯胺酚靜脈注射市場變數、趨勢、範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 乙醯胺酚靜脈注射液市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章乙醯胺酚靜脈注射液市場：適應症估計及趨勢分析

  • 細分儀表板
  • 乙醯胺酚靜脈注射液市場：適應症變化分析
  • 乙醯胺酚靜脈注射液按適應症的市場前景
  • 2018-2030年市場規模、預測及趨勢分析
  • 疼痛
  • 發燒

第5章乙醯胺酚靜脈注射液市場：應用估算及趨勢分析

  • 細分儀表板
  • 乙醯胺酚靜脈注射液市場：應用變化分析
  • 乙醯胺酚靜脈注射液市場－依應用前景
  • 2018-2030年市場規模、預測及趨勢分析
  • 外科手術
  • 非手術手術

第6章乙醯胺酚靜脈注射市場：最終用途估計與趨勢分析

  • 細分儀表板
  • 乙醯胺酚靜脈注射液市場：最終用途變化分析
  • 依最終用途分類的乙醯胺酚靜脈注射液市場前景
  • 2018-2030年市場規模、預測及趨勢分析
  • 醫院
  • 診所
  • 其他

第7章乙醯胺酚靜脈注射市場：區域估計及趨勢分析

  • 區域儀表板
  • 2018-2030年市場規模及預測趨勢分析
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭格局

  • 市場參與企業分類
  • 主要市場參與企業的最新趨勢和影響分析
  • 2024 年企業市場佔有率分析
  • 主要企業簡介
    • Mallinckrodt（Mallinckrodt Pharmaceuticals）
    • Cipla Inc.
    • Lupin
    • Dr. Reddy's Laboratories Ltd.
    • Aurobindo Pharma
    • Sun Pharmaceutical Industries Ltd.
    • Novartis AG
    • Pfizer, Inc.
    • Abbott
    • Sanofi
    • Bristol-Myers Squibb Company
Product Code: GVR-4-68039-965-3

Paracetamol IV Market Growth & Trends:

The global paracetamol IV market size is estimated to reach USD 994.23 million by 2030, expanding at a CAGR of 3.43% from 2025 to 2030, according to a new report by Grand View Research, Inc. The rising prevalence of chronic disorders that requires pain management is expected to facilitate the growth of the industry during the forecast period. The enhanced usage of acetaminophen to reduce the dependence on opioids for pain management is projected to accelerate the growth in demand for paracetamol IV. The IV paracetamol is a stable acetaminophen form and is intended for mild to moderate pain management. It is used over other NSAIDs to treat patients with a history of peptic ulcers and asthma, as it lacks interference with the function of platelets.

Rising cases of patients reporting postoperative pain are expected to propel the demand for drugs and products with fewer side effects. As per the article published in the International Journal of Surgery, in March 2022, 77% - 83% of patients in the U.S., 80% of patients in Thailand, 76% of patients in Sweden, and 29.5% of patients in Germany reported severe to moderate postoperative pain. The IV paracetamol is intended for usage in the treatment of acute postoperative pain and during the surgeries, such as orthopedic, dental, and gynecological. A rise in the number of surgeries performed and patients experiencing post-operative pain is expected to create a high product demand in the years to come. However, the availability of multiple generic products is expected to hinder the industry during the forecast period.

For instance, in December 2020, Sandoz International GmbH launched a generic acetaminophen injection in the U.S. The product will be available in 10 mg/mL concentration, in a 100 mL vial for the treatment of mild to moderate in conjunction with opioid analgesics for pediatric patients. Key players operating in the global industry are following various strategic initiatives for business expansion and to gain a competitive edge over others. For instance, in December 2021, Leucadia Pharmaceuticals launched and announced the availability of a generic acetaminophen injection, which is an FDA-approved generic that corresponds to the acetaminophen injection manufactured by Mallinckrodt Pharmaceuticals.

Paracetamol IV Market Report Highlights:

  • Based on application, the pyrexia segment is estimated to register the fastest CAGR from 2025 to 2030.
  • The growth of the segment is attributed to the rapid action & effectiveness of paracetamol being administered intravenously.
  • The surgical application segment held the largest revenue share in 2024 due to the increased usage of paracetamol IV for the treatment of post-operative pain and rapid relief from fever.
  • North America dominated the global industry in 2024 owing to high product usage for reducing the dependence of the economy on opioids for the management of pain.
  • Companies are focusing on geographical expansion by adopting strategies, such as collaborations, partnerships, new product launches, and strategic initiatives to maintain a competitive position in the industry.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Indication
    • 1.2.2. Application
    • 1.2.3. End Use
    • 1.2.4. Regional Scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Regional outlook
  • 2.4. Competitive Insights

Chapter 3. Paracetamol IV Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising cases of postoperative pain
      • 3.2.1.2. Increasing prevalence of chronic disorders
      • 3.2.1.3. Increasing use of intravenous paracetamol in combination with NSAIDs and narcotics
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Overdose of paracetamol IV
      • 3.2.2.2. Availability of generic products
  • 3.3. Paracetamol IV Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape

Chapter 4. Paracetamol IV Market: Indication Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Paracetamol IV Market: Indication Movement Analysis
  • 4.3. Paracetamol IV Market by Indication Outlook (USD Million)
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.5. Pain
    • 4.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Pyrexia (Fever)
    • 4.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Paracetamol IV Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Paracetamol IV Market: Application Movement Analysis
  • 5.3. Paracetamol IV Market by Application Outlook (USD Million)
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.5. Surgical
    • 5.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Non-surgical
    • 5.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Paracetamol IV Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Paracetamol IV Market: End Use Movement Analysis
  • 6.3. Paracetamol IV Market by End Use Outlook (USD Million)
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.5. Hospitals
    • 6.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Clinics
    • 6.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Others
    • 6.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Paracetamol IV Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Dashboard
  • 7.2. Market Size & Forecasts Trend Analysis, 2018 to 2030
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
  • 8.2. Recent Developments & Impact Analysis by Key Market Participants
  • 8.3. Company Market Share Analysis, 2024
  • 8.4. Key Company Profiles
    • 8.4.1. Mallinckrodt (Mallinckrodt Pharmaceuticals)
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. Cipla Inc.
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. Lupin
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. Dr. Reddy's Laboratories Ltd.
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Aurobindo Pharma
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. Sun Pharmaceutical Industries Ltd.
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Novartis AG
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. Pfizer, Inc.
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. Abbott
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. Sanofi
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product benchmarking
      • 8.4.10.4. Strategic initiatives
    • 8.4.11. Bristol-Myers Squibb Company
      • 8.4.11.1. Company overview
      • 8.4.11.2. Financial performance
      • 8.4.11.3. Product benchmarking
      • 8.4.11.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Regulatory Framework
  • Table 4 Global Paracetamol IV Market, By Region, 2018 - 2030 (USD Million)
  • Table 5 Global Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 6 Global Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 7 Global Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 8 North America Paracetamol IV Market, By Country, 2018 - 2030 (USD Million)
  • Table 9 North America Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 10 North America Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 11 North America Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 12 U.S. Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 13 U.S. Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 14 U.S. Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 15 Canada Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 16 Canada Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 17 Canada Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 18 Mexico Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 19 Mexico Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 20 Mexico Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 21 Europe Paracetamol IV Market, By Country, 2018 - 2030 (USD Million)
  • Table 22 Europe Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 23 Europe Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 24 Europe Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 25 U.K. Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 26 U.K. Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 27 U.K. Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 28 Germany Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 29 Germany Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 30 Germany America Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 31 France Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 32 France Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 33 France Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 34 Spain Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 35 Spain Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 36 Spain Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 37 Italy Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 38 Italy Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 39 Italy Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 40 Denmark Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 41 Denmark Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 42 Denmark Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 43 Sweden Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 44 Sweden Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 45 Sweden Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 46 Norway Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 47 Norway Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 48 Norway Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific Paracetamol IV Market, By Country, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 51 Asia Pacific Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 52 Asia Pacific Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 53 China Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 54 China Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 55 China Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 56 Japan Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 57 Japan Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 58 Japan Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 59 India Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 60 India Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 61 India Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 62 South Korea Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 63 South Korea Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 64 South Korea Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 65 Australia Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 66 Australia Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 67 Australia Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 68 Thailand Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 69 Thailand Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 70 Thailand Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 71 Latin America Paracetamol IV Market, By Country, 2018 - 2030 (USD Million)
  • Table 72 Latin America Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 73 Latin America Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 74 Latin America Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 75 Brazil Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 76 Brazil Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 77 Brazil Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 78 Argentina Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 79 Argentina Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 80 Argentina Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 81 MEA Paracetamol IV Market, By Country, 2018 - 2030 (USD Million)
  • Table 82 MEA Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 83 MEA Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 84 MEA Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 85 South Africa Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 86 South Africa Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 87 South Africa Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 88 UAE Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 89 UAE Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 90 UAE Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 91 Saudi Arabia Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 92 Saudi Arabia Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 93 Saudi Arabia Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 95 Kuwait Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 96 Kuwait Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research approaches
  • Fig. 2 Value chain-based sizing & forecasting
  • Fig. 3 Market formulation & validation
  • Fig. 4 Paracetamol IV market segmentation
  • Fig. 5 Market driver analysis (current & future impact)
  • Fig. 6 Market restraint analysis (current & future impact)
  • Fig. 7 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 8 Porter's five forces analysis
  • Fig. 9 Global Paracetamol IV market: Indication outlook and key takeaways
  • Fig. 10 Global Paracetamol IV market: Indication movement analysis
  • Fig. 11 Pain market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 12 Pyrexia (Fever) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 13 Global Paracetamol IV market: Application type outlook and key takeaways
  • Fig. 14 Global Paracetamol IV market: Application type movement analysis
  • Fig. 15 Surgical market estimates and forecast, 2018 - 2030
  • Fig. 16 Non-Surgical market estimates and forecast, 2018 - 2030
  • Fig. 17 Global Paracetamol IV market: End use outlook and key takeaways
  • Fig. 18 Global Paracetamol IV market: End use movement analysis
  • Fig. 19 Hospital pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Clinics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 North America Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 U.S. Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Canada Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Mexico Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Europe Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 UK Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Germany Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 France Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Italy Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Spain Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Denmark Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Sweden Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Norway Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Asia Pacific Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Japan Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 China Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 India Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Australia Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Thailand Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 South Korea Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Latin America Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Brazil Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Argentina Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 MEA Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 South Africa Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Saudi Arabia Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 UAE Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Kuwait Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 List of key emerging company's/disruptors/innovators